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Dynamic contrast-enhanced computed tomography (DCE-CT) and Positron Emission 
Tomography/Computed Tomography (PET/CT) have a high reported accuracy for the 
diagnosis of malignancy in solitary pulmonary nodules.  The aim of this study was to 
compare the accuracy and cost-effectiveness of these. 
Methods:  
In this prospective multicentre trial, 380 participants with a solitary pulmonary nodule (8-
30mm) and no recent history of malignancy underwent DCE-CT and PET/CT. All patients 
underwent either biopsy with histological diagnosis or completed CT follow-up.  Primary 
outcome measures were sensitivity, specificity, and overall diagnostic accuracy for PET/CT 
and DCE-CT. Costs and cost-effectiveness were estimated from a healthcare provider 
perspective using a decision-model.  
Results:  
312 participants (47% female, 68.1±9.0 years) completed the study, with 61% rate of 
malignancy at 2 years.  The sensitivity, specificity, positive predictive value and negative 
predictive values for DCE-CT were 95.3% [95% CI 91.3;97.5], 29.8% [95% CI 22.3;38.4], 
68.2% [95% CI 62.4%;73.5%] and 80.0% [95% CI 66.2;89.1] respectively, and for PET/CT were 
79.1% [95% CI 72.7;84.2], 81.8% [95% CI 74.0;87.7], 87.3%[95% CI 81.5;91.5) and 71·2% 
[95% CI 63.2;78.1].  The area under the receiver operator characteristic curve (AUROC) for 
DCE-CT and PET/CT was 0.62 [95%CI 0.58;0.67] and 0.80 [95%CI 0.76;0.85] respectively 
(p<0.001).  Combined results significantly increased diagnostic accuracy over PET/CT alone 
(AUROC=0.90 [95%CI 0.86;0.93], p<0.001). DCE-CT was preferred when the willingness to 
pay per incremental cost per correctly treated malignancy was below £9000.  Above £15500 
a combined approach was preferred. 
Conclusions:  
PET/CT has a superior diagnostic accuracy to DCE-CT for the diagnosis of solitary pulmonary 
nodules. Combining both techniques improves the diagnostic accuracy over either test alone 
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What is the key question?  
Which out of dynamic contrast enhanced CT (DCE-CT) and PET/CT is the most accurate and 
cost effective approach to the diagnosis of solitary pulmonary nodules between 8 and 30mm 
in size. 
What is the bottom line? 
While DCE-CT is more sensitive, PET/CT has higher overall accuracy for the characterisation 
of solitary pulmonary nodules. Combining the metabolic and perfusion data from the two 
techniques may be more accurate and cost-effective. 
Why read on? 
Solitary pulmonary nodules form an opportunity to treat cancer at a potentially curative stage, 
however only a minority of nodules will be malignant. A cost effective and accurate 




Despite a declining incidence in many first world countries, lung cancer remains the leading 
cause of cancer related death worldwide 1. A proportion of patients with lung cancer 
present with a solitary pulmonary nodule (SPN) on diagnostic imaging tests, which 
represents an important group of patients as it represents early disease with excellent 
survival rates following  radical treatment2. However, not all SPNs are due to lung cancer 
and the accurate characterisation of SPNs is an on-going diagnostic challenge with 
significant associated health costs. With the advent of national lung cancer screening 
programs, the number of patients with a SPN requiring further investigation will increase 
substantially 3. 
 
Due to the association between nodule size and likelihood of malignancy, current 
management strategies are directed by nodule size. Nodules <5mm require no follow-up, 
while nodules  ≥8mm in diameter require further diagnostic work-up with 18Fluorine 
Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography 
(PET/CT) or biopsy 4. However, both procedures are not without limitations; biopsy is 
invasive and PET/CT is expensive and has limited availability.  Dynamic contrast-enhanced 
computed tomography (DCE-CT) allows quantification of the enhancement of pulmonary 
nodules following administration of intravenous iodine-based contrast material5.  The 
enhancement reflects the extent of vascularity with high sensitivity and moderate specificity 
for the diagnosis of SPNs 6. DCE-CT may be a more cost-effective approach in the diagnostic 
work-up of nodules than PET/CT 7 although this evidence is weak. The studies were 
predominantly single-centred, did not directly compare PET with DCE-CT, included 
pulmonary masses as well as nodules, or used older PET technology with poor spatial 
resolution7,8.  The British Thoracic Society (BTS) guidelines called for further comparative 
studies comparing PET/CT with DCE-CT before it can be considered as a viable alternative 4. 
 
This multicentre trial compares the diagnostic accuracy and cost-effectiveness of DCE-CT 
with PET/CT in the assessment of solitary pulmonary nodules.  
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Materials and Methods 
This prospective multicentre observational study assesses the diagnostic performance and 
incremental value of DCE-CT, compared with PET/CT in a cohort of patients with SPN in 
accordance with the guidance for the methods of technology appraisal issued by NICE 9.  
The full trial protocol has been published 10 and registered on Clinical trials.gov 
(NCT02013063). The SPUtNIk Trial was approved by the South West Research Ethics 
Committee Centre (12/SW/0206, UK). All participants provided written informed consent.  
 
Settings and participants 
Participants with a SPN were recruited from secondary and tertiary outpatient settings at 16 
hospitals within the UK. Inclusion criteria were: Soft tissue solitary dominant pulmonary 
nodule of ≥ 8mm and ≤30mm on axial plane measured on lung window using conventional 
CT scan with no other ancillary evidence strongly indicative of malignancy (e.g. distant 
metastases or unequivocal local invasion); >18 years of age.  Presence of other small lesions 
<4mm that would normally be disregarded, meant the patient could be included. Exclusion 
criteria were: Pregnancy; History of malignancy within the past 2 years; Confirmed aetiology 
of the nodule at the time of qualifying CT scan; Biopsy of nodule prior to DCE-CT scan; 
Contra-indication to imaging examinations, potential radiotherapy or surgery. 
 
Recruited patients underwent a PET/CT and DCE-CT   to assess their pulmonary nodules. 
PET/CT and DCE-CT scans were ideally performed within 14 days, with up to 21 days allowed 
between scans when sites had difficulty with scheduling. Following the PET/CT and DCE-CT 
investigations, management of the SPN was directed by the local/specialist lung 
multidisciplinary team meeting (MDT). 
 
Objectives 
The primary objective of the trial was to determine the diagnostic performances and cost-
effectiveness of DCE-CT and PET/CT for the characterisation of SPNs. The secondary 
objectives were to assess whether combining DCE-CT with PET/CT is more accurate and/or 




All 25 PET/CT scanners (Supplementary Material) underwent baseline accreditation and 
annual quality assurance testing by the UK PET Core Lab 11. All PET/CTs were reported by 
accredited PET/CT reporters, blind to the histology results. The CT features were graded as: 
0 - Round, well-defined lesion with laminated or popcorn calcification; 1 = Inflammatory 
features e.g. air bronchograms, enfolded lung; 2 = Smooth well-defined margins, uniform 
density; 3 = Lobulated, spiculated or irregular margins; 4 = Evidence of distant metastases 
(i.e. M1 disease). The PET features were graded as 0 = No visible uptake; 1 = Uptake less 
than mediastinal blood pool; 2 = Uptake comparable to mediastinal blood pool; 3 = Uptake 
greater than mediastinal blood pool; 4 = Evidence of distant metastases (i.e. M1 disease). 
The maximum standardised uptake value (SUVmax) was also recorded. The combined 
PET/CT assessment was classified as positive for malignancy if one of the following criteria 
were met: Grade 4 on PET or CT, Grade 3 on PET and ≥ Grade 2 on CT, or Grade 2 on PET 




The CT scans were acquired on 16 scanners (Supplementary material). The protocol for 
performing and analysing the DCE-CT has been reported previously 12.  Following a bolus of 
1·4 ml/kg iodinated contrast material (300 mg/ml) injected intravenously at 2ml/sec, images 
were acquired at 100kV at 0s, 60s, 120s, 180s and 240s and reported by local trained 
physicians. For each time point, the attenuation of the nodule was measured in Hounsfield 
units (HU) by placing a region of interest (ROI) occupying approximately 70% of the nodule’s 
diameter. All attenuation analyses were performed in the axial plane using mediastinal 
windows.   Maximum nodule enhancement was calculated as: highest post contrast 
attenuation value - baseline attenuation. A Peak Enhancement (PE) ≥20HU was considered 




The primary outcomes were the comparative diagnostic accuracy of DCE-CT and PET/CT, 
and the cost-effectiveness of their implementation within the diagnostic work-up pathway 
for SPNs.  
 
For the diagnostic accuracy, the reference standard was histological diagnosis, or MDT 
decision at 2 years follow-up.  In the absence of histological diagnosis, assessment is based 
on nodule growth as per BTS guidelines (nodule growth is defined as an increase in its 
diameter or volume of ≥ 25%) 4. Stability of nodule size was regarded as an indication of 
benign diagnosis following completion of 2 years CT follow up for 2D measurements or 1 
year for 3D volumetric monitoring 4. This reference standard was performed blind to the 
DCE-CT results, but not to the results of the PET/CT which was performed as part of the 
clinical care. The participants’ clinical notes were reviewed at 24 months to determine 
patient management including investigative procedures, surgical interventions, treatment 
and associated inpatient stays.  
 
Sample size calculation 
At study inception 375 participants was considered an adequate number for the study to be 
informative, whilst still being achievable within a reasonable timeframe. Published 
sensitivity for PET/CT varies between 77 and 96% (pooled weighted average: 92%) with 
specificity between 76 and 100% (pooled weighted average: 90%) 5. Published sensitivity 
and specificity values for DCE-CT vary between 81 and 100% (pooled weighted average: 
87%) and 29 and 100% (pooled weighted average: 83%) respectively 5,6,13,14. The mean 
prevalence of malignancy in indeterminate SPN has been reported as 68·5% 7. At this 
prevalence, a sample size of 375 would produce 257 malignant and 118 benign SPNs. This 
will give confidence limits for sensitivity and specificity of DCE-CT of 87% ± 4·1% and 83% ± 
6·8% and PET/CT of 92% ± 3·3% and 90% ± 5·4% respectively. 
  
When considering the accuracy of both tests in combination, those with a negative DCE-CT 
are classed as benign, while a positive DCE-CT progressed to PET/CT. If the PET/CT was 
positive the nodule was classed as ‘malignant’ and those PET/CTs which were negative were 
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classed as ‘benign’. The specificity of this process is the same as using PET/CT alone but we 
need to estimate the sensitivity. Based on previous data of 130 malignant tumours, 114 
were both DCE-CT and PET/CT positive. This suggests the sensitivity of the joint testing 
procedure is 114 / 130 = 0·877. Compared to the PET/CT sensitivity of 0·92, the joint testing 
approach is projected to reduce sensitivity by about 4%. A total sample size of 288 patients 
is required (including 197 with malignant tumours) to detect a 4% reduction in sensitivity for 
the combined approach compared to PET/CT alone.15 This calculation assumes an 80% 
power, 5% significance level and prevalence of malignancy of 0·685.  
 
Statistical analysis - Accuracy 
We considered the diagnostic accuracy of positive PET/CT and DCE-CT, both separately and 
in conjunction, in relation to a diagnosis of lung cancer by 2 years. The diagnostic accuracy 
of the tests was assessed by sensitivity, specificity, and overall diagnostic accuracy using the 
pre-specified classifications (including the combination of tests) and cut-offs. Further 
exploratory analyses were performed considering the full spectrum of cut-offs using 
SUVmax and PE separately and in combination using logistic regression. Receiver operator 
characteristic curves were constructed for these exploratory analyses and an optimal cut-
point keeping the sensitivity above 90% and maximising specificity within this limitation was 




A decision analytic model (Supplementary Figure S1) on which the cost-consequence and 
cost-effectiveness analyses were based, was developed to synthesize evidence and estimate 
the expected costs and consequences of each imaging strategy for a cohort of people aged 
68 years, presenting with a SPN (8-30mm) and managed according to the imaging test 
result.  The time horizon of the model was two-years but life-expectancy and quality 
adjusted life years (QALYs) were extrapolated over the patient lifetime.  
 
Imaging test accuracy and probabilities of following different management pathways were 
sourced from the trial, the literature, and clinical expert opinion. Cost estimates were 
derived from routine sources (i.e. NHS reference costs, etc) as well as from the literature 
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and were inflated where necessary, to 2018 prices. Further evidence required to estimate 
life expectancy and health related quality of life were sourced from the literature. The data 
used in the economic model are reported in Supplementary Tables S9-S13. 
 
Parameter uncertainty within the model was addressed using probabilistic sensitivity 
analysis.  Multiple variable one-way sensitivity was also used to identify those parameters to 
which costs and the proportion of accurately treated cases and malignancies were most 
sensitive to. Scenario analyses explored the impact of structural assumptions (i.e. exclusion 
of indeterminate results) on the costs and consequences. Model validation involved the 
comparison of results to an independent model, developed to answer the same decision 




Of the 2541 patients screened (Figure 1) 19% (n=413) had more than one nodule, 14% 
(n=296) declined, 14% (n=306) had a nodule out size range and 12% (n=264) had malignancy 
within the last two years. Of the 380 patients recruited, 312 (53% male, median age of 69 
years, IQR = 62 to 74, range = 35 to 89) completed both DCE-CT and PET/CT examinations 
and 2 years of follow-up and comprise the dataset for analysis (See Table 1 for Baseline 
characteristics). Ex-smokers accounted for 57% with 25% still smoking. The median 
pulmonary nodule diameter on baseline CT was 15mm (IQR = 12-20).  
 
Lung cancer was confirmed in 191/312 (61%) participants (Table 2).  The commonest cancer 
type was non-small cell lung cancer (145/191, 76%).  Of these, the most common subtypes 
were adenocarcinoma (107/145, 74%) and squamous cell carcinoma (30/145, 21%).  In 20 
cases, it was not possible to achieve a histological diagnosis due to co-morbidities and 
therefore an MDT decision based on clinical and radiological diagnosis was made.  In 11 of 
these cases, treatment with stereotactic ablative radiotherapy (SABR) was undertaken.  
Benign disease was diagnosed in 121/312 participants.  This was confirmed by biopsy in 27 
cases and using up to two years CT follow-up in 94 patients.  
 
Of the 312 participants 49% had their DCE-CT on the same day as their PET/CT, 90% within 
two weeks (median delay = 1 day, IQR  0 to 8, range = 0 to 32 days) and 98% within three 
weeks. On the baseline PET/CT and DCE-CT the majority of the nodules were classified as 
Grade 3 (Table 3). On PET/CT 161 (52%) had 18F-FDG uptake greater than the mediastinal 
blood pool (grade 3), 10% had similar uptake (grade 2), 21% had uptake less than the 
mediastinal blood pool (grade 1) and 17% had no uptake (grade 0). The mean of the 
SUVmax was 4·75±5.65 (Range: 0-35·3).  There was lymph node involvement in 40 (13%) 
cases and 4 (1%) were found to have metastatic disease. On DCE-CT the mean Peak 
Enhancement (PE) was 48·6±28.3 HU (Range 0-179), with a PE ≥ 20 HU reached in 267 (86%) 
of patients. 
 
The sensitivity, specificity, positive predictive value and negative predictive values for DCE-
CT were 95.3% [95% CI 91.3;97.5], 29.8% [95% CI 22.3;38.4], 68.2% [95% CI 62.4%;73.5%] 
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and 80.0% [95% CI 66.2;89.1] respectively, and for PET/CT were 79.1% [95% CI 72.7;84.2], 
81.8% [95% CI 74.0;87.7], 87.3%[95% CI 81.5;91.5) and 71·2% 
[95% CI 63.2;78.1].   
 
The sensitivity, specificity, positive predictive value and negative predictive values for DCE-
CT was 95·3% (95% CI 91·3;97·5), 29·8% (95% CI 22.3;38·4), 68.2% [95% CI 62.4%;73.5%] and 
80.0% [95% CI 66.2;89.1] respectively, and for PET/CT grade was 79·1% (95% CI 72·7;84·2), 
81·8% (95% CI 74·0;87·7), 87.3%[95% CI 81.5;91.5) and 71·2% [95% CI 63.2;78.1] (Table 4). 
Using an SUVmax of ≥2·5 as a cut-off, the sensitivity and specificity was 76·4% (95% CI 
69·9;81·9) and 81·5% (95% CI 73·6;87·5) respectively. When combining DCE-CT with PET/CT 
(Table 4) the performance is similar to PET/CT alone, but with a slightly lower sensitivity of 
75·4% and a slightly higher specificity of 83·5%.  
 
Figure 2 shows Receiver Operating Characteristic (ROC) curves for the pre-specified rules 
and the best performing combinations following exploratory modelling with logistic 
regression using the key elements from the imaging scans. The area under the receiver 
operator characteristic curve (AUROC) was 0·62 (95% CI 0·58;0·67) for DCE-CT and 0·80 
(95%CI 0·76;0·85) for PET/CT (p<0.0001 for difference). SUVmax ≥2·5 as a cut off was no 
more accurate than the combined PET/CT grading (AUROC 0·79 (95% CI 0·74;0·84), p=0.48 
for difference).  Exploratory modelling of the various parameters at different thresholds 
showed SUVmax had the best diagnostic accuracy with an AUROC of 0·87 (95% CI 
0·83;0·91). Addition of CT grade to DCE-CT PE slightly increased the accuracy of DCE-CT from 
an AUROC of 0.74 (95% CI 0.68 to 0.80) for PE alone, to an AUROC of 0.77 (95% CI 0.71 to 
0.83) for combined grade and PE, but this remained lower than that of PET/CT. Combining 
DCE-CT PE with SUVmax provided the best accuracy with an AUROC of 0·90 (95% CI 
0·86;0·93, p=0.029 versus SUVmax alone).  
 
The single best cut-off options for the exploratory models are in Table 5 (including both a 
90% minimum sensitivity cut point and a balanced sensitivity and specificity cut point). 
Using an SUV threshold of ≥ 2·3 produces an increased performance of 80.5% sensitivity, 
78.2% specificity, 71·5% NPV, and 85·5% PPV. Using a threshold probability of ≥ 0·53 
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produces 84·7% sensitivity, 77·3% specificity, 76·0% NPV, and 85·6% PPV for the model 
combining SUVmax and DCE-CT PE  
 
Cost-consequence analysis showed DCE-CT was on average least costly (£3,305 [95% CI 
£2,952;£3,746]) compared with PET/CT (£4,013 [95% CI £3,673;£4,498]) or combined DCE-
CT & PET/CT (£4,058 [95% CI £3,702;£4,547]) (see also Table 6). PET/CT resulted on average 
in more correctly managed malignant cases than DCE-CT (44% [95% CI 39%;49%] vs. 40% 
[95% CI 35%;45%]) and the combination improved this proportion (47% [95% CI 42%;51%]). 
PET/CT resulted on average in more appropriately managed cases compared with DCE-CT 
for overall management (82% [95% CI 79%;85%] vs. 78% [95% CI 74%;82%]), life expectancy 
(10.50 years [95% CI 9.91;11.15] vs. 10.22 years [95% CI 9.60;10.91]), QALYs (7.64 [95% CI 
7.19;8.15] vs. 7.43 [95% CI 6.94;7.96]), and the proportion of patients receiving delayed 
treatment (20% [95% CI 17%;24%] vs. 26% [95% CI 21%;30%]). The combination further 
improved outcomes compared to PET/CT (Table 6).  
 
The incremental cost per malignant case treated was £11,395 for the comparison of the 
combined approach (DCE-CT / PET/CT) compared with DCE-CT.  The incremental cost per 
correctly managed case was similarly £11,323.  These values do not reflect statistical 
imprecision and the likelihood that DCE-CT, PET/CT and a combined approach might be 
considered cost-effective at different threshold values for society’s willingness to pay for a 
malignant case treated, and a correctly managed case are presented in Figure 3A and B 
respectively. PET/CT was unlikely to be considered cost-effective.  DCE-CT was most likely 
cost-effective when the willingness to pay (WTP) ceiling ratio per correctly managed case 
was below £11,395.  Above £16,000 a combined approach would be cost-effective.  When 
society is willing to pay no more than £9000 per correctly treated malignancy DCE-CT was 




In this multicentre trial we have found that: (1) PET/CT is more accurate than DCE-CT for the 
diagnosis of solitary pulmonary nodules; (2) combining perfusion data from DCE-CT and 
metabolic data from PET may yield a more accurate assessment of the nodule than either 
alone; (3) This combined approach is the most cost effective at higher willingness to pay 
thresholds. 
 
The strengths of this study are that it is the largest diagnostic accuracy study of PET/CT for 
the diagnosis of SPNs, the second largest study of the diagnostic accuracy of DCE-CT, and 
the only multicentre, multivendor study directly comparing the two techniques making the 
results more precise and generalizable than previous work. The sensitivity and specificity for 
PET/CT were 79·1% (95% CI 72·7;84·2) and 81·8% (95% CI 74·0;87·7) similar to the meta-
analysis of 21 studies with 1,557 nodules, where the pooled sensitivity was 89% (95% CI 
87;91) and specificity of 70% (95% CI, 66;73) 16. The lower sensitivity but higher specificity 
reflects the use of PET/CT grading rather than SUVmax in SPUTNIK with the CT grading 
improving the specificity 17.  In this meta-analysis 16, many studies were retrospective and 
used an infrequently pre-defined SUVmax cut-off point which may have overly optimised 
sensitivity. Our exploratory analysis reinforces that if an optimised SUVmax is used rather 
than the PET/CT grading, the sensitivity is 91.0% (95% CI 86·1;94·3) and specificity was 
63.0% (54·1;71·2), closer matching the meta-analysis.   
 
In our study, DCE-CT had the higher sensitivity of 95·3% with the penalty of low specificity of 
29·8%. Compared to a pooled sensitivity and specificity of 95% and 76% in a recent meta-
analysis of DCE-CT (23 studies with 2397 participants)18, our cohort study had much lower 
specificity and the reasons for this are not clear. The closest results to our own come from 
Swensen et al., who examined the diagnostic accuracy of DCE-CT in 356 patients across 7 
sites, finding a sensitivity of 98% and specificity of 58% using a threshold of 15HU 14 and the 
largest DCE-CT study with 486 patients with sensitivity and specificity of 98% and 46% 
respectively 19. This latter study demonstrated that using both wash-in and wash-out 
kinetics improved the specificity of DCE-CT with minimal impact on sensitivity, but imaged 
out to 5 minutes providing more time for contrast to wash out.  Future studies focusing on 
 16 
adding wash-out and the nodule characteristics to DCE-CT alongside volumetric analysis will 
be useful to determine if these may improve the diagnostic performance of this technique.  
 
Our findings support the BTS and Fleischner guidelines, which recommend biopsy or PET/CT 
for nodules 8-30mm in diameter 4,20. When considering access and cost, DCE-CT is the most 
cost-effective approach due to a lower unit price similar to a health economic analysis 
performed by Gould et al 8. However, this strategy results in a lower number of correctly 
treated cases. At higher willingness to pay thresholds, DCE-CT followed by PET/CT if positive, 
becomes the most cost-effective strategy. DCE-CT can be performed during the initial CT if a 
nodule is found and indeed many institutes conduct an adaptive imaging strategy during CT 
examinations. Such a practice would have substantial benefits for the patient, minimising 
additional hospital visits and making the initial CT more accurate.  Orlacchio et al. have 
previously demonstrated the feasibility of incorporating DCE-CT at the end of the PET image 
acquisition reducing the need for multiple visits and appointments 21.  
 
However, it is important to be cautious as the difference in costs between PET/CT alone and 
a combination of DCE-CT and PET/CT was small on average and may lack economic 
significance. The combination of DCE-CT and PET/CT was the best alternative strategy when 
comparing patient outcomes, correctly identifying the highest proportion of patients with 
malignant disease (46·7%), the lowest proportion of malignant cases left without treatment 
(13·7%), and achieved the lowest proportion of inappropriate treatment in patients with a 
benign nodule (9·0%). These results led to the appropriate management of 84·4% of 
patients.  
 
A limitation of this study is the applicability of our results to SPNs found at lung screening, a 
setting  where the prevalence of malignancy appears to be lower (National Lung Screening 
Trial 15·0% malignancy in 10-30mm nodules and NELSON trial 15·2% malignancy in nodules 
>10mm) 22,23.  The 61% malignancy rate of nodules in this study represents indeterminate 
SPNs found in normal clinical practice and is in keeping with previous meta-analyses of MRI 
and PET in SPNs 16,24. Previous work has shown the sensitivity of a technique to be relatively 
robust to disease prevalence and for the specificity to increase with falling prevalence 25. 
Therefore, it can be postulated that the diagnostic accuracy of the techniques would be 
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similar, or even improved, in a screening population. However, this requires further 
prospective evaluation in a screening detected cohort. The current study had a low rate of 
diagnosis of infectious diseases as the underlying aetiology of the nodules, thus the accuracy 
and thresholds may not be translatable to environments where such conditions are more 
endemic.  Finally, only solid or part solid nodules were included in the current study where 
the solid component was sufficient to allow for PET and DCECT quantification. As a result 
the findings cannot be extrapolated to ground glass nodules nor part-solid nodules with 
minimal solid component.  
 
In conclusion, while DCE-CT is more sensitive, PET/CT has significantly higher overall 
accuracy for the characterisation of solitary pulmonary nodules. Combining the metabolic 
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Table 1: Baseline characteristics and Medical History of the study participants (n=312) 
 
















Location of SPN 
Left Lower Lobe 
Left Upper Lobe 
Right Lower Lobe 
Right Middle Lobe 




















Medical History of 
Cardiovascular Disease 
Any Cardiovascular Disease 
Missing 








Medical History of 
Respiratory Disease 














Medical History of 
Inflammatory Disease 








Medical History of Infectious 
Disease 











Variable (unit)*  Number (percentage) 
Previous Inhalational 
Exposures 















Abbreviations: SD= standard deviation, SPN=solitary pulmonary nodule. 
*Subgroups may add to more than the Group totals as patients may have more than one 
condition within any disease grouping 
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Non-Small cell lung cancer 
Adenocarcinoma 
Squamous cell carcinoma 
Large cell undifferentiated 























Carcinoid tumour 8 (30%) 4 (4%) 0 (0%) 12 (6%) 
Small cell lung cancer 0 (0%) 6 (6%) 1 (2%) 7 (4%) 
Radiological diagnosis only* 0 (0%) 13(7%) 7 (4%) 20 (5%) 
Other 4 (15%) 1 (1%) 1 (2%) 6 (3%) 
No further information 
provided 
0 (0%) 0 (0%) 1 (2%) 1 (1%) 
Benign 
(N=121) 
Benign nodule not 
otherwise specified 
17 (57%) 36 (53%) 7 (35%) 61 (50%) 
Hamartoma 7 (23%) 13 (19%) 5 (25%) 26 (21%) 
Infection / Inflammation 3 (10%) 15 (22%) 5 (25%) 24 (20%) 
Other 1 (3%) 0 (0%) 0 (0%) 1 (1%) 
No further information 
provided 
2 (7%) 4 (6%) 3 (15%) 9 (7%) 
* Includes those undergoing Stereotactic ablative radiotherapy based on radiology alone  
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Table 3: Initial CT, DCE-CT and PET/CT scan information (n=312) 




























































































DCE-CT Peak Enhancement Mean ± SD 48·6 ± 28·3 
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Table 3: Initial CT, DCE-CT and PET/CT scan information (n=312) 
































Diagnosis according to peak 






Abbreviations: SPN= solitary pulmonary nodule, CT= Computed tomography, DCE-CT= 
dynamic contrast-enhanced computed tomography , PET/CT=18Fluorine 
Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, SUVmax= 
maximum standardised uptake value, HU= Hounsfield unit.  
 




















(Peak enhancement ≥ 20) 
182/191 - 95·3%  
(91·3% to 97·5%) 
36/121 - 29·8% 
(22·3% to 38·4%) 
36/45 - 80·0% 
(66·2% to 89·1%) 
182/267 - 68·2% 
(62·4% to 73·5%) 
218/312 – 69·9% 
(64·6% to 74·7%) 
PET/CT 
(Based on PET and CT grading) 
151/191 – 79·1% 
(72·7% to 84·2%)  
99/121 – 81·8% 
(74·0% to 87·7%) 
99/139 – 71·2% 
(63·2% to 78·1%) 
151/173 – 87·3% 
(81·5% to 91·5%) 
250/312 – 80·1% 




(Based on an SUV maximum ≥ 2·5) 
146/191 – 76·4% 
(69·9% to 81·9%) 
97/119 – 81·5% 
(73·6% to 87·5%) 
97/142 – 68·3% 
(60·3% to 75·4%) 
146/168 – 86·9% 
(81·0% to 91·2%) 
243/310 – 78·4% 
(73·5% to 82·6%) 
Combination of DCE-CT and PET/CT* 
144/191 - 75·4% 
(68·8% to 81·0%) 
101/121 - 83·5% 
(75·8% to 89·0%) 
101/148 - 68·2% 
(60·4% to 75·2%) 
144/164 - 87·8% 
(81·9% to 92·0%) 
245/312 – 78·5% 
(73·6% to 82·7%) 
Abbreviations: DCE-CT= dynamic contrast-enhanced computed tomography , PET/CT=18Fluorine Fluorodeoxyglucose Positron Emission 
Tomography/Computed Tomography, CI= Confidence interval. 
*Where if DCE-CT is negative the nodule is considered benign, while if it is positive it progresses to PET/CT with adjudication then based upon 





Table 5: Diagnostic performance of the best performing Exploratory models (N=312) 
 



















(Positive if ≥ 1·8) 
173/190 – 91·0% 
(86·1% to 94·3%) 
75/119 – 63·0% 
(54·1% to 71·2%) 
75/92 – 81·5% 
(72·4% to 88·1%) 
173/217 – 79·7% 
(73·9% to 84·5%) 
248/309 – 80·3% 
(75·5% to 84·3%) 
DCE-CT Peak Enhancement  
(Positive if ≥ 25) (N=311) 
176/190 – 92·6% 
(88·0% to 95·6%) 
47/121 – 38·8% 
(30·6% to 47·7%) 
47/61 – 77·1% 
(65·1% to 85·8%) 
176/250 – 70·4% 
(64·5% to 75·7%) 
223/311 – 71·7% 
(66·5% to 76·4%) 
SUVmax and DCE-CT Peak enhancement 
(Positive if Probability ≥ 0·43) (N=308) 
171/189 – 90·5% 
(85·5% to 93·9%) 
82/119 – 68·9% 
(60·1% to 76·5%) 
82/100 – 82·0% 
(73·3% to 88·3%) 
171/208 – 82·2% 
(76·4% to 86·8%) 
253/308 – 82·1% 
(77·5% to 86·0%) 




(Positive if ≥ 2·3) 
153/190 – 80·5% 
(74·3% to 85·5%) 
93/119 – 78·2% 
(69·9% to 84·6%) 
93/130 – 71·5% 
(63·3% to 78·6%) 
153/179 – 85·5% 
(79·6% to 89·9%) 
246/309 – 79·6% 
(74·8% to 83·7%) 
DCE-CT Peak Enhancement 
(Positive if ≥ 38·5) (N=311) 
147/190 – 77·4% 
(70·9% to 82·7%) 
80/121 – 66·1% 
(57·3% to 73·9%) 
80/123 – 65·0% 
(56·3% to 72·9%) 
147/188 – 78·2% 
(71·8% to 83·5%) 
227/311 – 73·0%  
(67·8% to 77·6%) 
SUVmax and DCE-CT Peak Enhancement 
(Positive if Probability ≥ 0·53) (N=308) 
160/189 – 84·7% 
(78·8% to 89·1%) 
92/119 – 77·3% 
(69·0% to 83·9%) 
92/121 – 76·0% 
(67·7% to 82·8%) 
160/187 – 85·6% 
(79·8% to 89·9%) 
252/308 – 81·8% 
(77·1% to 85·7%) 
 
Abbreviations: SUVmax= maximum standardised uptake value, DCE-CT= dynamic contrast-enhanced computed tomography. 
 
 
Table 6: Costs and consequences results for base case analysis from a healthcare system 
perspective. 
Single Outcomes PET/CT DCE-CT DCE-CT /PET/CT 
Cost  £4013 (206) £3305 (199) £4058 (210) 
Accurately managed cases  82·0% (1·6%) 77·8% (2·0%) 84·4% (1·4%) 
Malignancies treated  44·2% (2·5%) 40·1% (2·5%) 46·7% (2·4%) 
QALYS 7·64 (0·25) 7·43 (0·26) 7·76 (0·24) 
Life expectancy (years) 10·5 (0·32) 10·22 (0·34) 10·65 (0·31) 
Delayed or no treatment 
20·31% 
(1·84%) 
25·63% (2·15%) 17·18% (1·59%) 
Malignancies missed  16·2% (1·68%) 20·49% (2·04%) 13·71% (1·43%) 
Benign cases treated 9·91% (1·25%) 9·8% (1·25%) 9·0% (1·23%) 
Operative deaths 1·0% (0·05%) 0·92% (0·05%) 1·05% (0·05%) 
Operative deaths for benign cases 0·17% (0·02%) 0·16% (0·02%) 0·15% (0·02%) 
Operative deaths for malignant cases 0·96% (0·05%) 0·87% (0·05%) 1·01% (0·05%) 
 
Values reported as Mean (SD). 
Abbreviations: DCE-CT= Dynamic contrast-enhanced computed tomography , 
PET/CT=18Fluorine Fluorodeoxyglucose Positron Emission Tomography/Computed 













Figure 2: ROC curves comparing PET/CT grading, SUVmax, peak enhancement and a 
combination of the variables 
 
Aberviations: DCE-CT= Dynamic contrast-enhanced computed tomography, 
PET/CT=18Fluorine Fluorodeoxyglucose Positron Emission Tomography/Computed 





Figure 3: Cost-effectiveness acceptability curves for the 3 imaging approaches for cost per 
correctly treated malignancy (A) and per correctly managed case (B). 
 
 
Willingness to pay is expressed in £GBP. The x-axis represents the willingness to pay 
threshold for each correctly treated or diagnosed case, while the y axis represents the 
proportion of model iterations in which a particular imaging strategy is the most cost-
effective approach at each of the willingness to pay thresholds. For example, below a 
willingness to pay threshold of £10,000, DCE-CT is the most cost-effective in 100% of model 
iterations.  
